U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07253116) titled 'A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors' on Nov. 19.
Brief Summary: This is a Phase I/II, open-label, preliminary study of safety, tolerability, pharmacokinetics, and efficacy. The study comprises three parts: a Dose Escalation cohort, a Dose Expansion cohort, and an Efficacy Expansion cohort.
Dose Escalation cohort aims to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary efficacy of WJ22096 Tablets in patients with advanced solid tumors for whom standard therapies have failed, are not tolerated, or for whom no standard therapy exists.
Dose Expansion c...